loading
Avenue Therapeutics Inc stock is traded at $1.01, with a volume of 96,778. It is down -9.09% in the last 24 hours and down -22.48% over the past month. Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
See More
Previous Close:
$1.10
Open:
$1.1
24h Volume:
96,778
Relative Volume:
0.26
Market Cap:
$2.13M
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.2651
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-23.08%
1M Performance:
-22.48%
6M Performance:
-64.16%
1Y Performance:
-91.53%
1-Day Range:
Value
$1.00
$1.14
1-Week Range:
Value
$1.00
$1.34
52-Week Range:
Value
$1.00
$15.00

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Name
Name
Avenue Therapeutics Inc
Name
Phone
781-652-4500
Name
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Name
Employee
3
Name
Twitter
@avenuethera
Name
Next Earnings Date
2024-12-11
Name
Latest SEC Filings
Name
ATXI's Discussions on Twitter

Compare ATXI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATXI
Avenue Therapeutics Inc
1.01 2.13M 0 -10.38M -12.45M -3.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.12 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
689.65 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
634.98 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.70 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.86 27.34B 3.30B -501.07M 1.03B -2.1146

Avenue Therapeutics Inc Stock (ATXI) Latest News

pulisher
02:53 AM

Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February - Defense World

02:53 AM
pulisher
Mar 02, 2025

BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

KESTRA MEDICAL TECHNOLOGIES, LTD. Prices IPO at $14.00-$16.00 Per Share (KMTS) - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Arbe Robotics Ltd. (NASDAQ:ARBE) Short Interest Up 56.5% in February - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Avenue Therapeutics (NASDAQ:ATXI) vs. Teva Pharmaceutical Industries (NYSE:TEVA) Head to Head Review - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World

Feb 28, 2025
pulisher
Feb 12, 2025

The Surprise Surge: How Travere Therapeutics Defied Wall Street Trends - Jomfruland.net

Feb 12, 2025
pulisher
Feb 12, 2025

Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

ATXIAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - br.ADVFN.com

Feb 11, 2025
pulisher
Feb 06, 2025

Sionna Therapeutics Prices Upsized Initial Public Offering - GlobeNewswire

Feb 06, 2025
pulisher
Feb 05, 2025

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance

Feb 05, 2025
pulisher
Feb 05, 2025

Here’s Why Third Avenue Small-Cap Value Fund Re-established a Position in Five Point Holdings (FPH) - Yahoo Finance

Feb 05, 2025
pulisher
Jan 28, 2025

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 28, 2025

Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com

Jan 28, 2025
pulisher
Jan 27, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Trajan Group Director Increases Stake Through Options - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 24, 2025

FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan

Jan 24, 2025
pulisher
Jan 24, 2025

Wall Street-Heavily Traded - WDRB

Jan 24, 2025
pulisher
Jan 24, 2025

PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com

Jan 24, 2025
pulisher
Jan 24, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Fortune Brands plans Deerfield headquarters expansion, hundreds of new jobs; ‘A great endorsement of Lake County’ - Chicago Tribune

Jan 23, 2025
pulisher
Jan 22, 2025

Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Another strong year for K Street heading into Trump 2.0, tax fights - POLITICO

Jan 22, 2025
pulisher
Jan 21, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Jan 21, 2025
pulisher
Jan 19, 2025

AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jan 19, 2025
pulisher
Jan 19, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 19, 2025
pulisher
Jan 17, 2025

Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing - Barchart

Jan 17, 2025
pulisher
Jan 17, 2025

Form S-1 Odyssey Therapeutics, - StreetInsider.com

Jan 17, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $11.50 - Defense World

Jan 13, 2025
pulisher
Jan 11, 2025

Avadel Pharmaceuticals (NASDAQ:AVDL) Hits New 1-Year Low After Analyst Downgrade - Defense World

Jan 11, 2025

Avenue Therapeutics Inc Stock (ATXI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Avenue Therapeutics Inc Stock (ATXI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
KRANZLER JAY D
Director
Nov 05 '24
Sale
2.24
61
137
559
KRANZLER JAY D
Director
Sep 30 '24
Buy
2.50
497
1,242
620
KRANZLER JAY D
Director
Sep 27 '24
Buy
2.40
3
7
123
$78.82
price down icon 3.23%
$23.07
price up icon 1.68%
$34.02
price up icon 1.11%
$20.07
price down icon 2.46%
biotechnology ONC
$244.35
price down icon 10.01%
$112.86
price down icon 0.06%
Cap:     |  Volume (24h):